Trilaciclib Partnership Expands Myeloprotection to 11 Asia-Pacific Markets

Trilaciclib, the first-in-class cyclin-dependent kinase 4/6 inhibitor designed for myelopreservation, is set to reach 11 new Asia-Pacific markets through a commercialization deal with Menarini. For biopharma watchers, this partnership highlights the growing interest in supportive care innovations that can improve chemotherapy tolerability and outcomes in extensive-stage small cell lung cancer.

On July 21, 2026, Menarini Asia-Pacific and Pharmacosmos A/S announced an exclusive partnership to bring Cosela (trilaciclib) to patients across 11 Asia-Pacific markets. The deal centers on the first-in-class prophylactic therapy designed to protect bone marrow from chemotherapy-induced myelosuppression (CIM), a persistent and debilitating side effect in patients with extensive-stage small cell lung cancer (ES-SCLC). Under the agreement, Menarini will handle registration, reimbursement, commercialization, and distribution in Australia, Hong Kong/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. This collaboration represents a strategic push to address a significant unmet need in oncology supportive care in a region that bears a heavy lung cancer burden.

“

On July 21, 2026, Menarini Asia-Pacific and Pharmacosmos A/S announced an exclusive partnership to bring Cosela (trilaciclib) to patients across 11 Asia-Pacific markets.

Cosela is a transient CDK4/6 inhibitor that temporarily arrests hematopoietic stem and progenitor cells in the G1 phase of the cell cycle, shielding them from the cytotoxic effects of chemotherapy. Approved by the U.S. Food and Drug Administration in February 2021, it remains the sole prophylactic option available to reduce the frequency of CIM in adults receiving platinum/etoposide-containing or topotecan-containing regimens for ES-SCLC. Clinical trials demonstrated its ability to decrease the duration and incidence of severe neutropenia, anemia, and thrombocytopenia, thereby mitigating treatment delays, dose reductions, and hospitalizations. For a cancer with a five-year survival rate below 5%, any intervention that enables patients to complete intended chemotherapy courses can be clinically meaningful.

Asia-Pacific markets are particularly promising for Cosela. According to the World Health Organization, the region accounts for over half of the world's lung cancer cases, with small cell lung cancer comprising about 15% of all lung cancers. ES-SCLC is predominantly treated with chemotherapy, making CIM a common challenge. The 11 territories covered by this partnership range from high-income health systems like Australia and Singapore with robust reimbursement frameworks to emerging markets like Vietnam and Indonesia where out-of-pocket costs and fragmented care can complicate access. Menarini Asia-Pacific’s established commercial presence and local market knowledge—built through a portfolio of over 40 marketed brands in the region—positions it to navigate complex regulatory and pricing landscapes effectively. The company’s CEO Glen Godresse described Cosela as 'an important advancement in oncology supportive care' that can 'make a meaningful difference for patients,' emphasizing the partnership’s alignment with Menarini’s mission to deliver innovative therapies through its end-to-end capabilities.

For Pharmacosmos, a Danish specialty pharmaceutical company with deep expertise in iron carbohydrate complexes and supportive care, the deal marks a significant step in the global commercial rollout of its key oncology asset. Klaus Abel, Vice President of Global Commercial Partnerships at Pharmacosmos, noted that the firm sought a partner with 'capabilities to support every stage of the journey, from registration through to commercialization and patient access.' By retaining marketing authorization while leveraging Menarini’s distribution network, Pharmacosmos gains rapid market penetration without building its own infrastructure in a fragmented region. The financial terms were not disclosed, but the exclusive nature and broad geographic scope suggest a meaningful revenue-sharing agreement that could generate substantial royalty income once launches are complete.

The competitive landscape for myeloprotective agents is currently wide open. While granulocyte colony-stimulating factors (G-CSFs) are routinely used reactively to boost neutrophil counts, Cosela is administered prior to chemotherapy and acts prophylactically across multiple blood cell lines, a distinct advantage. No other approved prophylactic therapies exist, though G1 Therapeutics (now owned by Pharmacosmos) originally developed trilaciclib and retains rights in the U.S. and other markets. In the APAC region, local generics and biosimilars dominate supportive care, but a first-in-class branded agent could command premium pricing if pharmacoeconomic data demonstrate reductions in hospitalization and transfusion costs. Real-world evidence from early access programs in the region will be critical to convincing payers of its cost-effectiveness.